Industry
Biotechnology
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 1:44 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 11:41 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 9:15 pm
Portfolio Pulse from Benzinga Newsdesk
March 21, 2024 | 12:47 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 10:42 am
Portfolio Pulse from Benzinga Newsdesk
March 19, 2024 | 9:00 pm
Portfolio Pulse from Happy Mohamed
March 19, 2024 | 8:12 pm
Portfolio Pulse from Avi Kapoor
February 02, 2024 | 7:32 pm
Portfolio Pulse from Avi Kapoor
February 02, 2024 | 6:18 pm
Portfolio Pulse from Benzinga Insights
February 02, 2024 | 5:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.